In conclusion, the therapeutic effects of T2D ASCs were reduced compared to healthy cells, and such reduction might have been caused by less secretion of cytokines that mediate the protection of ASCs including VEGF, HGF, and TGF-β. The gene discussed is HGF; the disease is type 2 diabetes mellitus.